PCSK9 抗体 (AA 231-330)
(1 reference)-
- 抗原 See all PCSK9 抗体
- PCSK9 (Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9))
-
抗原表位
- AA 231-330
- 适用
- 人, 大鼠, 小鼠
-
宿主
- 兔
-
克隆类型
- 多克隆
-
标记
- This PCSK9 antibody is un-conjugated
-
应用范围
- Western Blotting (WB), ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))
- 交叉反应
- 人, 小鼠, 大鼠
- 纯化方法
- Purified by Protein A.
- 免疫原
- KLH conjugated synthetic peptide derived from human PCSK9/NARC1
- 亚型
- IgG
- Top Product
- Discover our top product PCSK9 Primary Antibody
-
anti-Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) (C-Term) antibody
PCSK9 适用: 人 WB, IF 宿主: 兔 Polyclonal unconjugated
anti-Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) (AA 164-428) antibodyPCSK9 适用: 大鼠 WB, IHC, IP, ICC 宿主: 小鼠 Monoclonal C5 unconjugated
anti-Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) (C-Term) antibodyVerified PCSK9 适用: 人 WB, ELISA, IHC 宿主: 山羊 Polyclonal unconjugated
anti-Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) (AA 153-183), (N-Term) antibodyPCSK9 适用: 人 WB, FACS, IHC (p) 宿主: 兔 Polyclonal RB19130 unconjugated
anti-Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) (AA 144-173) antibodyPCSK9 适用: 人 WB, ELISA, IHC, FACS 宿主: 兔 Polyclonal unconjugated
anti-Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) (AA 479-508) antibodyPCSK9 适用: 人 WB, ELISA, IHC, FACS 宿主: 兔 Polyclonal unconjugated
anti-Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) antibodyPCSK9 适用: 人, 大鼠, 小鼠 WB, IHC 宿主: 兔 Polyclonal unconjugated
anti-Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) (AA 479-508), (C-Term) antibodyPCSK9 适用: 人 WB, FACS, IHC (p) 宿主: 兔 Polyclonal RB18880 unconjugated
anti-Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) (AA 153-380) antibodyPCSK9 适用: 人 WB, ELISA, IHC, IF 宿主: 兔 Polyclonal unconjugated
anti-Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) (AA 164-428) antibodyPCSK9 适用: 大鼠 WB, IHC, IP, ICC 宿主: 兔 Polyclonal unconjugated
-
- 应用备注
-
WB 1:300-5000
ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 - 限制
- 仅限研究用
-
- 状态
- Liquid
- 浓度
- 1 μg/μL
- 缓冲液
- 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
- 储存液
- ProClin
- 注意事项
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
- 储存条件
- 4 °C,-20 °C
- 储存方法
- Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
- 有效期
- 12 months
-
-
: "Effects of Tanshinone IIA on the modulation of miR‑33a and the SREBP‑2/Pcsk9 signaling pathway in hyperlipidemic rats." in: Molecular medicine reports, Vol. 13, Issue 6, pp. 4627-35, (2016) (PubMed).
-
: "Effects of Tanshinone IIA on the modulation of miR‑33a and the SREBP‑2/Pcsk9 signaling pathway in hyperlipidemic rats." in: Molecular medicine reports, Vol. 13, Issue 6, pp. 4627-35, (2016) (PubMed).
-
- 抗原
- PCSK9 (Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9))
- 别名
- Narc1 (PCSK9 产品)
- 别名
- FH3 antibody, HCHOLA3 antibody, LDLCQ1 antibody, NARC-1 antibody, NARC1 antibody, PC9 antibody, AI415265 antibody, AI747682 antibody, Narc1 antibody, proprotein convertase subtilisin/kexin type 9 antibody, proprotein convertase subtilisin/kexin type 9 L homeolog antibody, PCSK9 antibody, pcsk9.L antibody, pcsk9 antibody, Pcsk9 antibody
- 背景
-
Synonyms: FH3, PC9, NARC1, LDLCQ1, NARC-1, HCHOLA3, Proprotein convertase subtilisin/kexin type 9, Neural apoptosis-regulated convertase 1, Proprotein convertase 9, Subtilisin/kexin-like protease PC9, PCSK9, PSEC0052
Background: Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments (PubMed:18039658). Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation (PubMed:18799458, PubMed:17461796, PubMed:18197702, PubMed:22074827). Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway (PubMed:18660751). Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways.
- 基因ID
- 255738
- UniProt
- Q8NBP7
-
